title: Azimilide pharmacokinetics following intravenous and oral administration of a solution and capsule formulation.
abstract: Azimilide dihydrochloride (NE-10064) is a novel class III anti-arrhythmic agent that blocks both the slowly and rapidly acting components of the delayed rectifier potassium current of human atrial and ventricular myocytes. In clinical studies, azimilide reduced the frequency of symptomatic episodes of atrial fibrillation, atrial flutter, and paroxysmal supraventricular tachycardia. This study was conducted to characterize azimilide pharmacokinetics following single-dose administration of a 1 mg/kg intravenous infusion (18 min), 2 mg/kg oral solution, and a 150 mg orally administered capsule. This was a three-period, randomized, crossover study in 27 healthy, drug-free (including caffeine and alcohol), non-smoking male volunteers (mean [SD]; age, 25.9 [1.0] years; weight 74.3 [0.7] kg; 23 Caucasians and 4 Hispanics). Blood and urine samples were collected for 27 days and analyzed for azimilide using HPLC with UV detection. Subjects were monitored for adverse events and abnormalities in clinical laboratory tests, vital signs, and electrocardiography (including Holter monitoring). Mean (%CV) azimilide parameters were total clearance = 0.143 L/h/kg (38%), renal clearance = 0.014 L/h/kg (35%), steady-state volume of distribution = 13.2 L/kg (23%), and terminal exponential half-life = 78.8 h (44%). Similar parameter estimates were obtained following oral administration. Both the oral solution and capsule formulations were completely absorbed. In addition, the rate (Cmax) and extent of absorption (AUC) following oral administration of the capsule dosage form were bioequivalent to the oral solution with means for times of maximum blood concentration of 7.08 and 7.18 hours for the oral solution and capsule, respectively. Azimilide dihydrochloride was generally well tolerated in all subjects.
authors.affiliation: Procter & Gamble Pharmaceuticals, Health Care Research Center, Mason, Ohio 45040-9462, USA.
authors.forename: A E
authors.initials: AE
authors.lastname: Corey
authors.forename: J R
authors.initials: JR
authors.lastname: Agnew
authors.forename: S N
authors.initials: SN
authors.lastname: Valentine
authors.forename: J D
authors.initials: JD
authors.lastname: Nesbitt
authors.forename: D L
authors.initials: DL
authors.lastname: Wagner
authors.forename: J H
authors.initials: JH
authors.lastname: Powell
authors.forename: G A
authors.initials: GA
authors.lastname: Thompson
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000493:pharmacokinetics*; D002214:Capsules; D002626:Chemistry, Pharmaceutical; D018592:Cross-Over Studies; D006801:Humans; D006827:Hydantoins; D007093:Imidazoles / Q000009:adverse effects / Q000493:pharmacokinetics*; D048289:Imidazolidines; D007275:Injections, Intravenous; D008297:Male; D010879:Piperazines / Q000009:adverse effects / Q000493:pharmacokinetics*; D012996:Solutions
chemical_list: D000889:Anti-Arrhythmia Agents; D002214:Capsules; D006827:Hydantoins; D007093:Imidazoles; D048289:Imidazolidines; D010879:Piperazines; D012996:Solutions; C086123:azimilide